Hui Hao-Shen
Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms.
Stetka J, Usart M, Kubovcakova L, Rai S, Rao T, Sutter J, Hao-Shen H, Dirnhofer S, Geier F, Bader M, Passweg J, Manolova V, Dürrenberger F, Ahmed N, Schroeder T, Ganz T, Nemeth E, Silvestri L, Nai A, Camaschella C, Skoda R. Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms. Blood 2023; 141:2127-2140.
Apr 27, 2023Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms.
Apr 27, 2023Blood 2023; 141:2127-2140
Stetka Jan, Usart Marc, Kubovcakova Lucia, Rai Shivam, Rao Tata Nageswara, Sutter Joshua, Hao-Shen Hui, Dirnhofer Stefan, Geier Florian, Bader Michael, Passweg Jakob R, Manolova Vania, Dürrenberger Franz, Ahmed Nouraiz, Schroeder Timm, Ganz Tomas, Nemeth Elizabeta, Silvestri Laura, Nai Antonella, Camaschella Clara, Skoda Radek C
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.
Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I, Girsberger S, Lehmann T, Passweg J, Stern M, Beisel C, Kralovics R, Skoda R. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 2014; 123:2220-8.
Jan 29, 2014Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.
Jan 29, 2014Blood 2014; 123:2220-8
Lundberg Pontus, Karow Axel, Nienhold Ronny, Looser Renate, Hao-Shen Hui, Nissen Ina, Girsberger Sabine, Lehmann Thomas, Passweg Jakob, Stern Martin, Beisel Christian, Kralovics Robert, Skoda Radek C
Transition to homozygosity does not appear to provide a clonal advantage to hematopoietic progenitors carrying mutations in TET2.
Schaub F, Lehmann T, Looser R, Hao-Shen H, Tichelli A, Skoda R. Transition to homozygosity does not appear to provide a clonal advantage to hematopoietic progenitors carrying mutations in TET2. Blood 2011; 117:2075-6.
Feb 10, 2011Transition to homozygosity does not appear to provide a clonal advantage to hematopoietic progenitors carrying mutations in TET2.
Feb 10, 2011Blood 2011; 117:2075-6
Schaub Franz X, Lehmann Thomas, Looser Renate, Hao-Shen Hui, Tichelli André, Skoda Radek C
Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms.
Schaub F, Looser R, Li S, Hao-Shen H, Lehmann T, Tichelli A, Skoda R. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood 2010; 115:2003-7.
Jan 8, 2010Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms.
Jan 8, 2010Blood 2010; 115:2003-7
Schaub Franz X, Looser Renate, Li Sai, Hao-Shen Hui, Lehmann Thomas, Tichelli André, Skoda Radek C